RecruitingPhase 4NCT04575844

Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic Syndrome

Sponsor

University of Virginia

Enrollment

80 participants

Start Date

Nov 1, 2020

Study Type

INTERVENTIONAL

Conditions

Metabolic Syndrome

Summary

The primary objective of this study is to examine whether exercise training alone, liraglutide treatment alone or exercise training plus liraglutide treatment increases cardiac and skeletal muscle microvascular blood volume, improves vascular function of the conduit vessels, and enhances insulin's metabolic action in humans with Metabolic Syndrome. Subjects will be randomized to one of the 4 groups: control, exercise training, liraglutide treatment, and exercise + liraglutide. They will be studied at the baseline and then after 24 weeks of intervention.

Eligibility

Min Age: 21 YearsMax Age: 60 Years

Inclusion Criteria16

Male or female ≥21 and ≤60 years old.
Body mass index >25 and ≤35 kg/m2 and is weight stable (<5 kg weight change in the past 6 months). BMI is limited to ≤35 kg/m2 for easier vascular access and cardiac imaging.
Meet 3 of 5 National Cholesterol Education Program Adult Treatment Panel III Metabolic Syndrome criteria:
Increased waist circumference (≥102 cm in men; ≥88 cm in women)
Elevated triglycerides (≥150 mg/dl)
Reduced HDL-cholesterol (<40mg/dl in men, <50 mg/dl in women)
High blood pressure (≥130 mmHg systolic or ≥85mmHg diastolic)
Elevated fasting glucose (≥100 mg/dl)
Subject may participate if on the following drugs, provided the drug doses have been stable for at least 3 months.
Ace inhibitor
ARB
HMG CoA reductase inhibitor
Beta blocker
Calcium channel blockers
Alpha-adrenergic antagonist
Statin

Exclusion Criteria10

A diagnosis of any type of diabetes or history of diabetes medication use
Recently active (>20 min of moderate/high intensity exercise, 2 times/week)
Subjects who are smokers or who have quit smoking <5 years
Subjects with hypertriglyceridemia (>400 mg/dl) or hypercholesterolemia (>260 mg/dl)
Subjects with BP>160/90
Subjects with a history of significant metabolic, cardiac, cerebrovascular, hematological, pulmonary, gastrointestinal, liver, renal, or endocrine disease or malignancy
Pregnant (as evidenced by positive pregnancy test) or nursing women
Subjects with contraindications to participation in an exercise training program
Allergic to perflutren
A prior use of Liraglutide